| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SSX4B |
| Uniprot No | O60224 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-188 aa |
| 活性数据 | MNGDDAFARRPRDDAQISEKLRKAFDDIAKYFSKKEWEKMKSSEKIVYVYMKLNYEVMTKLGFKVTLPPFMRSKRAADFHGNDFGNDRNHRNQVERPQMTFGSLQRIFPKIMPKKPAEEENGLKEVPEASGPQNDGKQLCPPGNPSTLEKINKTSGPKRGKHAWTHRLRERKQLVVYEEISDPEEDDE |
| 分子量 | 48.9 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人SSX4B蛋白的示例参考文献(内容为虚构，仅供参考模板)：
1. **"SSX4B as a novel cancer-testis antigen: Expression profiling and immune response analysis"**
- Schmidt, A. et al. *Journal of Cancer Immunology*.
- 摘要：研究揭示了SSX4B在多种肿瘤中的特异性表达，并证实其作为癌症睾丸抗原(CTA)的免疫原性，重组SSX4B蛋白体外诱导了T细胞应答，提示其作为免疫治疗靶点的潜力。
2. **"Cloning and prokaryotic expression of human SSX4B protein for antibody production"**
- Yang, L. et al. *Protein Expression and Purification*.
- 摘要：报道了SSX4B基因的克隆策略及在大肠杆菌中重组表达的方法，通过优化条件获得了高纯度蛋白，并利用该蛋白成功制备了特异性多克隆抗体。
3. **"Structural and functional analysis of SSX4B in transcriptional repression"**
- Chen, X. et al. *Cell Structure and Function*.
- 摘要：通过重组SSX4B蛋白结合体外实验，证明其KRAB结构域在招募组蛋白修饰酶中的关键作用，揭示了SSX4B参与基因沉默的分子机制。
4. **"Recombinant SSX4B protein vaccination suppresses tumor growth in murine models"**
- Wang, Y. et al. *Cancer Research*.
- 摘要：在小鼠模型中评估重组SSX4B蛋白疫苗的抗肿瘤效果，结果显示其可诱导特异性抗体和细胞免疫，显著抑制表达SSX4B的肿瘤生长。
(注：以上文献为示例模板，实际引用时需以真实文献为准。)
Recombinant human SSX4B protein is derived from the SSX (Synovial Sarcoma X breakpoint) gene family, which comprises several closely related members (SSX1-9) implicated in transcriptional regulation and oncogenesis. The SSX genes are classified as cancer/testis (CT) antigens due to their restricted expression in normal tissues (primarily testis) and reactivation in various cancers, including melanoma, breast cancer, and synovial sarcoma. SSX4B, a splice variant of SSX4. contains conserved domains such as the N-terminal Kruppel-associated box (KRAB)-like domain, which may mediate protein-protein interactions, and the C-terminal SSX repression domain (SSXRD), potentially involved in transcriptional modulation.
The recombinant SSX4B protein is typically produced via heterologous expression systems (e.g., E. coli, mammalian cells) for functional studies. Its oncogenic role remains partially characterized, but SSX proteins are proposed to interact with Polycomb group proteins, disrupting epigenetic regulation and promoting tumorigenesis. Additionally, SSX4B's immunogenic properties make it a candidate for cancer immunotherapy, as CT antigens can elicit immune responses against tumor cells. Research on recombinant SSX4B focuses on elucidating its biochemical interactions, validating its diagnostic or prognostic utility, and exploring its potential as a therapeutic target. Its restricted normal tissue expression minimizes off-target effects in treatments, enhancing its appeal in translational oncology.
×
